AstraZeneca PLC - Agreement to Supply Europe with COVID-19 Vaccine
AstraZeneca to supply
Company exploring further additional global
capacity to provide broad and equitable access
AstraZeneca has reached an agreement with
With today's agreement, the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative. The IVA is committed to providing equitable access to all participating countries across
AstraZeneca continues to build a number of supply chains in parallel across the world, including for
The Company has recently completed similar agreements with the
The Company's comprehensive pandemic response also includes rapid mobilisation of AstraZeneca's global research efforts to discover novel coronavirus-neutralising antibodies to prevent and treat progression of the COVID-19 disease, with the aim of reaching clinical trials in the next three to five months. Additionally, the Company has quickly moved into testing of new and existing medicines to treat the infection, including the CALAVI trials underway for Calquence (acalabrutinib) and the DARE-19 trial for Farxiga (dapagliflozin) in COVID-19 patients.
Today's announcement is not anticipated to have any significant impact on the Company's financial guidance for 2020; costs to manufacture the vaccine are anticipated to be offset by funding by governments.
ChAdOx1 nCoV-19, now known as AZD1222, was developed by Oxford University's
The recombinant adenovirus vector (ChAdOx1) was chosen to generate a strong immune response from a single dose and it is not replicating, so cannot cause an ongoing infection in the vaccinated individual. Vaccines made from the ChAdOx1 virus have been given to more than 320 people to date and have been shown to be well tolerated, although they can cause temporary side effects such as a temperature, influenza-like symptoms, headache or a sore arm.
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in
This information is provided by RNS, the news service of the
Quick facts: AstraZeneca
Market Cap: £114.16 billion
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE